Skip to NavigationSkip to content

immunooncology

GSK unveil appointment coup for board of directors

Published on: 21/07/17

GSK continue its appointment spree with a particularly notable staff acquisition, with leading immuno-oncology scientist, Dr Laurie Glimcher, joining its Board of Directors. It is becoming evident that new CEO, Emma Walmsley, is aiming to put her own stamp onto the company through a series of high-profile R&D appointments.

Bristol-Myers Squibb enters academic R&D tie-up

BMS building

Bristol-Myers Squibb and The Johns Hopkins University have entered into a collaboration agreement, as part of the pharma firm’s rare cancer R&D program in the US.

As part of the program, Bristol-Myers Squibb and the Johns Hopkins Kimmel Cancer Center will conduct a range of early phase clinical studies. BMS will also fund positions within the university’s fellowship program.

GSK and Merck to study immunotherapy combo in solid tumours

GSK building

GSK and Merck will start a Phase I clinical trial in humans to evaluate GSK’s investigational cancer drugs with the immuno-oncology drug Keytruda.

GSK will trial its immunotherapy GSK3174998 alone and in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab). The study will test the drugs in patients with locally advanced, recurrent or metastatic solid tumours that have progressed after standard treatment.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches